IP Library Granted Patent US 8,653,107
Granted Patent B2
US 8,653,107 · App. 13/188,862 · Granted Feb 18, 2014

Fentanyl composition for nasal administration

Inventors: Jesper Grarup (Roskilde, DK); Hanne Wulf Nielsen (Svenborg, DK)
Assignee: Takeda Pharma A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,653,107
App. No.
13/188,862
Granted
Feb 18, 2014
Kind
B2
Abstract

The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain relief has lower maximum plasma concentrations comparable to intravenous administration and results in lower rates of adverse events like respiratory depression, nausea and vomiting. Compositions for use in the method are also disclosed.

Claims (25)

1. A method for the treatment of pain in a mammal, which comprises intranasally administering, by a nasal spray to the nasal mucosal membrane of said mammal, a dosage unit in one administration by one delivery operation comprising a fentanyl salt in an amount equivalent to 70 to 500 μg of fentanyl in a solvent comprising water, wherein the dosage unit is in the form of a composition having a concentration equivalent to about 0.4 to 75 mg/ml of fentanyl.

2. The method according to claim 1 , wherein said administration comprises the delivery of a dosage unit equivalent to 75 to 300 μg of fentanyl.

3. The method according to claim 1 , wherein said administration comprises the delivery of a dosage unit equivalent to 75 μg of fentanyl.

4. The method according to claim 1 , wherein the mammal is a human.

5. The method according to claim 1 , wherein said administration comprises the delivery of a dosage unit equivalent to 100 μg of fentanyl.

6. The method according to claim 1 , wherein said administration comprises the delivery of a dosage unit equivalent to 150 μg of fentanyl.

7. The method according to claim 1 , wherein said administration comprises the delivery of a dosage unit equivalent to 200 μg of fentanyl

8. The method according to claim 1 , wherein said fentanyl salt is fentanyl citrate.

9. The method according to claim 1 , wherein said solvent further comprises isotonic saline, polyethylene glycol, or a combination thereof

10. The method according to claim 1 , wherein said solvent comprises about 95% -100% water.

11. The method according to claim 9 , wherein said dosage unit consists essentially of fentanyl salt and said solvent.

12. The method according to claim 1 , wherein the treatment is for alleviation or lessening of acute or breakthrough pain.

13. The method according to claim 1 , wherein the mammal further receives an analgesic.

14. The method according to claim 13 , wherein the analgesic is fentanyl, or a salt thereof.

15. The method according to claim 12 , wherein said acute or breakthrough pain comprises colic/biliary pain, trauma, postoperative pain, dental pain, orofacial pain, sympathetic pain syndrome, pancreatic pain, myocardial infarction pain, cancer pain, back pain, or pain during or after change of dressing.

16. The method according to claim 1 , wherein said administration comprises the delivery of a dosage unit equivalent to 400 μg of fentanyl.

17. The method according to claim 16 , wherein the treatment is for alleviation or lessening of breakthrough pain.

18. The method according to claim 1 , wherein the volume of the dosage unit is 10 to 200 μl.

19. The method according to claim 1 , wherein the volume of the dosage unit is 50 to 150 μl.

20. The method according to claim 1 , wherein the dosage unit is in the form of a composition having a concentration equivalent to about 0.5 to 20 mg/ml of fentanyl.

21. The method according to claim 1 , wherein the dosage unit is in the form of a composition having a concentration equivalent to about 0.6 to 15 mg/ml of fentanyl.

22. The method according to claim 1 , wherein the dosage unit is in the form of a composition having a concentration equivalent to about 0.7 to 12 mg/ml of fentanyl.

23. The method according to claim 1 , wherein the dosage unit is in the form of a composition having a concentration equivalent to about 0.75 to 10 mg/ml of fentanyl.

24. The method according to claim 1 , wherein the dosage unit is in the form of a composition having a concentration equivalent to about 0.75 to 8 mg/ml of fentanyl.

25. The method according to claim 1 , wherein the treatment is for pre-operative anesthesia.

Assignments (2)
NOTICE OF CHANGE OF ASSIGNEE'S ADDRESS Recorded Jan 21, 2015
From: TAKEDA PHARMA A/S
To: TAKEDA PHARMA A/S
Reel/Frame 034783/0364 →
CHANGE OF NAME Recorded Apr 8, 2013
From: NYCOMED DANMARK APS
To: TAKEDA PHARMA A/S
Reel/Frame 030167/0213 →
Priority Claims (1)
DK 2000 01154 · Jul 31, 2000 · national
Continuity (2)
Division 10343449
Related Publication 20110281914A1 · Nov 17, 2011